Education
About Us
Working with TipRanks
Follow Us
SeaStar Medical Holding (ICU)
NASDAQ:ICU
ICU Stock Chart & Stats
$2.30
-$0.08(-3.90%)
At close: 4:00 PM EST
$2.30
-$0.08(-3.90%)
Day’s Range― - ―
52-Week Range$2.20 - $25.70
Previous CloseN/A
Volume52.61K
Average Volume (3M)3.06M
Market Cap
$9.73M
Enterprise Value-$6.37M
Total Cash (Recent Filing)$13.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Mar 26, 2026EPS Estimate
-1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding3,800,000
10 Day Avg. Volume1,756,841
30 Day Avg. Volume3,057,972
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-3.33
Price to Sales (P/S)53.80
P/FCF Ratio-0.45
Enterprise Value/Market Cap-0.66
Enterprise Value/Revenue-7.23
Enterprise Value/Gross Profit-7.59
Enterprise Value/Ebitda0.46
Forecast
1Y Price Target
$6.00Price Target Upside160.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.36
Revenue Forecast (FY)$1.74M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressPromising interim results from the NEUTRALIZE-AKI trial and continued enrollment progress bolster the case for potential regulatory advancement and future market access.
Clinical ValidationPeer-reviewed post-approval clinical data showed positive early experience with QUELIMMUNE, reinforcing clinical credibility and supporting broader clinician adoption.
Commercial ExpansionExpansion of QUELIMMUNE commercialization into pediatric hospitals with several additional centers in the pipeline should broaden the customer base and increase long-term revenue potential.
Bears Say
Capital Raise And DilutionThe company's capital raise is expected to dilute existing shareholders, pressuring valuation metrics and implying the need for potential additional financings.
Revenue ShortfallReported revenue missed analyst expectations, signaling weaker commercial traction and raising questions about near-term growth momentum.
SeaStar Medical Holding News
ICU FAQ
What was SeaStar Medical Holding’s price range in the past 12 months?
SeaStar Medical Holding lowest stock price was $2.20 and its highest was $25.70 in the past 12 months.
What is SeaStar Medical Holding’s market cap?
SeaStar Medical Holding’s market cap is $9.73M.
When is SeaStar Medical Holding’s upcoming earnings report date?
SeaStar Medical Holding’s upcoming earnings report date is Mar 26, 2026 which is in 21 days.
How were SeaStar Medical Holding’s earnings last quarter?
SeaStar Medical Holding released its earnings results on Nov 13, 2025. The company reported -$1.3 earnings per share for the quarter, beating the consensus estimate of -$1.5 by $0.2.
Is SeaStar Medical Holding overvalued?
According to Wall Street analysts SeaStar Medical Holding’s price is currently Undervalued.
Does SeaStar Medical Holding pay dividends?
SeaStar Medical Holding does not currently pay dividends.
What is SeaStar Medical Holding’s EPS estimate?
SeaStar Medical Holding’s EPS estimate is -1.08.
How many shares outstanding does SeaStar Medical Holding have?
SeaStar Medical Holding has 3,800,000 shares outstanding.
What happened to SeaStar Medical Holding’s price movement after its last earnings report?
SeaStar Medical Holding reported an EPS of -$1.3 in its last earnings report, beating expectations of -$1.5. Following the earnings report the stock price went down -17.388%.
Which hedge fund is a major shareholder of SeaStar Medical Holding?
Currently, no hedge funds are holding shares in ICU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SeaStar Medical Holding
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
ICU Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call showcased several positive developments, including impressive survival results from Quellimmune therapy, significant revenue growth, and a high gross profit margin. The expansion of clinical sites and a strengthened financial position further underline the company's potential. However, the variability in sales and the increased enrollment requirement for the pivotal trial pose challenges. Despite these, the overall sentiment is positive with a strategic focus on overcoming hurdles and continuing growth.View all ICU earnings summariesICU Stock 12 Month Forecast
Average Price Target
$6.00
▲(160.87% Upside)
Technical Analysis
Ownership Overview
3.38% Insiders
6.28% Mutual Funds
<0.01% Other Institutional Investors
84.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---